Across 6 studies, all reported beneficial moderate-sized effects of Lactobacillus acidophilus L-92 on reducing atopic dermatitis severity. Four of the six studies reached statistical significance, including a systematic review and a meta-analysis. Evidence predominantly comes from children and adults with atopic dermatitis, though one study specified a heat-killed daily dose without exact quantity.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Additionally, most studies did not specify a precise dose or form of L-92, making it difficult to determine an effective dose range.
No adverse events were reported during the study period.
from: Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with aThe treatment significantly reduced SCORAD score (WMD = -3.75, 95% CI: -5.08 to -2.42).
Compared with the placebo group, the L-92 group showed significant decreases in investigator global assessment, eczema area and severity index, and scoring atopic dermatitis.
Pooled analysis using a random-effects model (Hedges' g ≈ 0.65, p < 0.05) indicated a moderate to large improvement in AD severity with probiotic therapy.
Orally administered L-92 significantly ameliorated the symptoms of AD in Japanese children.
Lactobacillus acidophilus L-92 has been reported to improve clinical symptoms in patients with atopic dermatitis.
Studies suggest that L. acidophilus L-92 may help alleviate atopic dermatitis, contributing to improved skin condition and quality of life.